TheraRadar
← Back
Data updated: Mar 29, 2026

EISAI INC

OncologyNeurologyMetabolic
Big Pharma

EISAI INC is a major pharmaceutical company focused on Oncology, Neurology, Metabolic. Key products include LENVIMA.

1990
Since
11
Drugs
-
Trials
12
Approved (2yr)

Key Drugs

LENVIMA
lenvatinib mesylate
FGFR1 5 indications · 2015
DAYVIGO
lemborexant
OX1R 1 indications · 2019

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

LEQEMBI 2026-01-16
Labeling
LEQEMBI 2025-12-15
Labeling
LEQEMBI 2025-12-15
Labeling
LEQEMBI IQLIK 2025-08-29
LEQEMBI 2025-08-21
Labeling
DAYVIGO 2025-02-19
Labeling
LENVIMA 2025-01-29
Efficacy
LEQEMBI 2025-01-24
Efficacy
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 52%
2 drugs Phase 3: 2 Phase 2: 11 Phase 1: 17
Neurology 41%
3 drugs Phase 3: 3 Phase 2: 6 Phase 1: 4
Metabolic 5%
0 drugs Phase 2: 2 Phase 1: 2
Respiratory 1%
0 drugs Phase 1: 1
Gastroenterology 1%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Takeda big-pharma
Oncology, Gastroenterology, Neurology, Metabolic
Amgen biotech
Oncology, Metabolic, Gastroenterology, Neurology
EMD SERONO INC biotech
Oncology, Neurology, Metabolic, Gastroenterology
GSK big-pharma
Respiratory, Oncology, Neurology
Sanofi big-pharma
Metabolic, Oncology, Respiratory